Related Experiment Video
Updated: Jun 13, 2026

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
Published on: May 9, 2020
Kynurenine pathway - a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease
K Pawlak1, M Myśliwiec, D Pawlak
1Department of Monitored Pharmacotherapy, Medical University, Bialystok, Poland.
Insights
Kynurenine pathway activation is linked to endothelial dysfunction and atherosclerosis progression in chronic kidney disease (CKD) patients. Inhibiting this pathway may offer a strategy to reduce atherosclerosis in this population.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Nephrology
Background:
- Endothelial dysfunction is a key factor in atherosclerotic cardiovascular disease.
- Kynurenine pathway activation is implicated in the pathogenesis of atherosclerosis.
Purpose of the Study:
- To investigate the relationship between kynurenine pathway metabolites, endothelial dysfunction markers, and atherosclerosis in chronic kidney disease (CKD) patients.
- To assess the association between kynurenine pathway activation and intima-media thickness (IMT) as an indicator of systemic atherosclerosis.
Main Methods:
- Cross-sectional study of 106 CKD patients.
- Measured plasma levels of kynurenine (KYN), 3-hydroxykynurenine (3-HKYN), kynurenic acid (KYNA), anthranilic acid (AA), quinolinic acid (QA), and endothelial dysfunction markers (vWF, TM, sICAM-1, sVCAM-1, sE-selectin, sP-selectin).
- Assessed intima-media thickness (IMT) as a measure of atherosclerosis.
Main Results:
- CKD patients showed significantly higher levels of kynurenines, vWF, TM, sICAM-1, sVCAM-1, and IMT compared to controls.
- Kynurenines were positively associated with endothelial dysfunction markers and IMT.
- Age, vWF, sVCAM-1, and QA were independent predictors of increased IMT.
Conclusions:
- A link exists between kynurenine pathway activation, endothelial dysfunction, and atherosclerosis progression in CKD.
- Targeting the kynurenine pathway could be a therapeutic strategy to mitigate endothelial dysfunction and atherosclerosis in CKD patients.
Purpose:
The endothelium dysfunction is an important component of atherosclertic cardiovascular disease. It has been also suggested that kynurenine pathway activation may be involved in the pathogenesis of this disease.
Material/Methods:
This is a cross-sectional study in chronic kidney disease (CKD) patients (n=106; 60 Males). The plasma markers of endothelial dysfunction and kynurenine (KYN), 3-hydroxykynurenine (3-HKYN), kynurenic acid (KYNA), anthranilic acid (AA) and quinolinic acid (QA) were measured in relation to an early indicator of the systemic atherosclerosis - intima-media thickness (IMT).
Results:
Kynurenines, von Willebrand factor (vWF), thrombomodulin (TM), soluble adhesion molecules (sICAM-1, sVCAM-1) and IMT in each uraemic group were significantly higher than in healthy people. In contrast, no significant differences in sE-selectin and sP-selectin concentrations were observed between CKD patients and controls. Kynurenines were positively associated with vWF, TM, sICAM-1 and sVCAM-1, whereas sP-selectin was inversely associated with the most of kynurenines. IMT was positively correlated both with kynurenines: KYN, 3-HKYN, QA as well as with endothelial markers: TM, vWF, sICAM-1 and sVCAM-1 (all p<0.01). Finally, multiple regression analysis identified age, vWF, sVCAM-1 and QA levels as the independent variables significantly associated with increased IMT in this population (adjusted r² = 0.51).
Conclusions:
This study suggests a relationship between kynurenine pathway activation, endothelial dysfunction and the progression of atherosclerosis in CKD patients. It opens a new idea that the inhibition of kynurenine pathway may provide an effective strategy to slow down endothelial dysfunction and thereby the prevalence of atherosclerosis in this population.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology
Coronary Artery Disease II: Pathophysiology
Hypertension II: Pathophysiology

